News Release 

Rejected and unfilled prescriptions for new, more expensive cholesterol drugs tied to higher heart, stroke risk

American Heart Association

DALLAS, July 23, 2019 - Patients appear to be at higher risk of heart problems or stroke when prescriptions for the newest cholesterol-lowering drugs are rejected by insurance companies or unfilled by patients, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

The drugs, PCSK9 inhibitors (PCSK9i), can substantially lower levels of low-density lipoprotein (LDL, the "bad" cholesterol) in the blood. But they are also more expensive than other prescription treatments - costing about $14,000 a year at the time this study was conducted in 2015 - 2017. Last fall, the American Heart Association encouraged drug companies to lower prices to improve patient access.

The study reviewed the medical records and pharmacy claims of about 139,000 high risk adults over a 29-month period after the drugs were first made available in 2015. On average patients' outcomes were tracked for 11.5 months from the prescription date.

Researchers found:

Insurers rejected about two-thirds of prescriptions for those at highest risk.

Patients were 16% more likely to have a cardiovascular event (such as heart attacks, unstable angina, angioplasty, coronary bypass surgery, cardiac arrest, and heart disease or stroke attributed to clogged arteries) if their prescription was rejected than if it was covered and filled for almost a year of treatment.

Patients were 21% more likely to have a cardiovascular event if they had a prescription approved but did not fill it.

"Our study shows that when high-risk groups of individuals with familial hypercholesterolemia or already established atherosclerotic disease are rejected for prescribed PCSK9i therapies it can have consequences," said lead author Kelly D. Myers, B.S., chief technology officer for The FH Foundation, a leading research and advocacy non-profit organization focused on reducing heart disease by driving scientific understanding and evidence-based care of familial hypercholesterolemia (FH).

"We have both treatment guidelines and available medications to help reduce cholesterol and associated cardiovascular events in the most vulnerable high-risk patients, and yet barriers in the healthcare system - such as higher treatment costs, tight restrictions on approvals, Medicare rules against co-payment assistance, and lack of coverage - are delaying treatment."

PCSK9i drugs are typically given as injections once or twice a month, often with other cholesterol-lowering drugs including statins. The newer medication is approved to treat two groups of high-risk patients: those with an inherited condition defined by a defect in how the body processes LDL called familial hypercholesterolemia (FH) and those with arterial plaque buildup who have high LDL despite other treatments.

Donald Lloyd-Jones, M.D., a member of the writing committee for the American Heart Association's 2018 cholesterol guidelines, noted this study reviewed data from 2015-2017, prior to several positive steps that have been taken to make this medication more relevant, available and affordable for the people who can best benefit from it.

"Following a thorough review of the science, the American Heart Association guidelines now support the use of PCSK9 inhibitors for certain populations - after use of statins and ezetimibe - and we encourage clinicians and payors to take this into consideration in determining prescription approvals," said Lloyd-Jones, chair of the Department of Preventive Medicine at Northwestern University. "Additionally, the Association has taken bold action in working directly with pharmaceutical companies to address the considerable costs that can hinder access to life-saving medications. So, we hope to see this trend turning and for future data to show that people have access to the medications they need and are using them to their greatest benefit."

Among other findings in the study:

Prescriptions written for women were more likely to be rejected than those for men.

Rejections were more common among both blacks and Hispanics than whites.

15% of prescriptions were abandoned by patients, a rate that researchers suspect was driven by high co-payments. The average copayment for abandoned prescriptions was $233.30 - more than $100 higher than for prescriptions that were covered.

About two-thirds of abandoned prescriptions were among Medicare patients.

The authors noted that the use of a large data set and length of time studied are key strengths of the research. But the data did not capture why claims were rejected, individuals' LDL levels, drug samples patients were given, patient deaths, and missed diagnoses of cardiovascular disease. They also noted potential biases of the study team - employees and advisers for the FH Foundation - adding that their research questions were rooted in patients' health concerns and experiences with prescription claim denials.

###

Co-authors are Niloofar Farboodi, M.Sc., M.P.H.; Mkaya Mwamburi, M.D., Ph.D., M.A.; William Howard, Ph.D.; David Staszak, Ph.D.; Samuel Gidding, M.D.; Seth J. Baum, M.D.; and Daniel J. Rader, M.D. and Katherine Wilemon, B.S., CEO and founder of The FH Foundation. Author disclosures are on the manuscript.

The FH Foundation funded the study.

Additional Resources:

Available multimedia is on right column of release link - https://newsroom.heart.org/news/rejected-and-unfilled-prescriptions-for-new-more-expensive-cholesterol-drugs-tied-to-higher-heart-stroke-risk?preview=25b93e6b69a5b8d981040e60a7312423

After July 23, view the manuscript and editorial online and AHA commentary by American Heart Association volunteer expert Donald Lloyd-Jones, M.D.

AHA News Release: Less than half of patients prescribed new cholesterol drug receive insurance approval

AHA News Release: The American Heart Association applauds corporate commitment to expanding access to lifesaving medicine

Follow AHA/ASA news on Twitter @HeartNews

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public's health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.